⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745320 | 1.00 | — | — | |
| SCHEMBL22652946 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL21200542 | 0.98 | SLC6A2 (0.31) | — | |
| SCHEMBL2373072 | 0.91 | SLC6A2 (0.31) | — | |
| SCHEMBL7852934 | 0.91 | SSTR4 (0.32) | — | |
| SCHEMBL7856435 | 0.91 | SSTR4 (0.35) | — | |
| SCHEMBL27893513 | 0.89 | — | — | |
| SCHEMBL27684537 | 0.89 | — | — | |
| SCHEMBL7853582 | 0.89 | SSTR4 (0.37) | — | |
| Hydrochloric Acid SCHEMBL28974480 | 0.89 | SLC6A2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617795-B2 | Substituted 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines, 5,7-dihydrofuro[3,4-d]pyrimidines, and pyrido[2,3-d]pyrimidines as KCC2 modulators | ASTRAZENECA AB (SE) | 2026-05-05 | — | — | US | disclosed |
| CN-119735594-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119684300-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119684299-A | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115298182-B | Fused pyrimidine compounds as KCC2 modulators | 阿斯利康(瑞典)有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119176847-A | Steroid compound, application thereof, preparation method and pharmaceutical composition containing steroid compound | 北京华睿鼎信科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240254083-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4337206-A1 | HETEROCYCLIC TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| CN-1219768-C | Quinoline derivatives as inhibitors of MEK enzymes | ASTRAZENECA AB (SE) | 2005-09-21 | — | — | CN | disclosed |
| CN-1365355-A | Quinoline derivatives as inhibitors of MEK enzymes | ASTRAZENECA AB (SE) | 2002-08-21 | — | — | CN | disclosed |
| EP-0719258-B1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMA CO LTD (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-5786367-A | OXYGEN SCAVENGERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-28 | — | — | US | disclosed |
| EP-0719258-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996002508-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |